Pfizer says keen to engage with AstraZeneca board
LONDON May 13 (Reuters) - U.S. drugmaker Pfizer kept up the pressure on bid target AstraZeneca on Tuesday, saying its offer represented compelling value for a company which would otherwise face challenges as a standalone firm.
Pfizer released a statement to set out its case for the deal, just hours before its chief executive appears in front of a British parliamentary committee to explain why he wants to acquire Britain's second largest drugmaker.
AstraZeneca has rejected a $106 billion bid from Pfizer but the U.S. group is widely expected to return with a higher offer later this week.
- Alabama man gets $1,000 in police settlement, his lawyers get $459,000
- Probe: Athletes took fake classes at University of North Carolina
- Canadian parliament gunman acted alone: police |
- Some U.S. hospitals weigh withholding care to Ebola patients
- Exclusive: Charred tanks in Ukraine point to Russian involvement